Vebreltinib for Advanced or Metastatic CCS

This is a prospective, cohort, multicenter study. Cohort 1 is treatment group. All eligible subjects will receive Vebreltinib (200 mg bid po) after signing the informed consent and meeting the inclusion/exclusion criteria, until disease progression, intolerable toxicity, or death. Subjects will undergo MET abnormality testing after enrollment, including MET amplification or MET protein overexpression. Cohort 2 is external reference group. Subjects diagnosed with CCS and met the inclusion criteria but refused to enter Cohort1 will receive the standard treatment decided by investigators. These

Trial Details

NCT ID
NCT07153887
Phase
PHASE2
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Vebreltinib
  • Standard medical treatment
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Age ≥12 years old, male or female;
  • ECOG PS score 0-2;
  • Histopathologically confirmed unresectable locally advanced or metastatic clear cell sarcoma;
  • Previous surgery, radiotherapy, or chemotherapy is allowed; patients who have used PD1/PDL1 for 4 months without effect are allowed to continue usi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →